BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qin Z, Yan A. QSAR studies on hepatitis C virus NS5A protein tetracyclic inhibitors in wild type and mutants by CoMFA and CoMSIA. SAR QSAR Environ Res 2020;31:281-311. [PMID: 32208783 DOI: 10.1080/1062936X.2020.1740889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ejeh S, Uzairu A, Shallangwa GA, Abechi SE, Ibrahim MT. In silico design and pharmacokinetics investigation of some novel hepatitis C virus NS5B inhibitors: pharmacoinformatics approach. Bull Natl Res Cent 2022;46. [DOI: 10.1186/s42269-022-00796-y] [Reference Citation Analysis]
2 Wu Y, Huo D, Chen G, Yan A. SAR and QSAR research on tyrosinase inhibitors using machine learning methods. SAR QSAR Environ Res 2021;32:85-110. [PMID: 33517778 DOI: 10.1080/1062936X.2020.1862297] [Reference Citation Analysis]
3 Huo D, Wang H, Qin Z, Tian Y, Yan A. Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR. Mol Divers 2021. [PMID: 34636023 DOI: 10.1007/s11030-021-10300-9] [Reference Citation Analysis]
4 Ejeh S, Uzairu A, Shallangwa GA, Abechi SE. Computational insight to design new potential hepatitis C virus NS5B polymerase inhibitors with drug-likeness and pharmacokinetic ADMET parameters predictions. Futur J Pharm Sci 2021;7. [DOI: 10.1186/s43094-021-00373-6] [Reference Citation Analysis]